Trial reportFrontiers in medicine2025
Enhanced efficacy of 0.05% cyclosporine a combined with absorbable punctal plugs in Sjögren's syndrome-associated dry eye: a paired-eye clinical trial.
Trial report in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07171710 (Comparative Evaluation of 0.05% Cyclosporine A Plus Absorbable Punctal Plugs Versus 0.05% Cyclosporine A Monotherapy in Sjögren's Syndrome-Associated Dry Eye), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Evaluation of 0.05% Cyclosporine A Plus Absorbable Punctal Plugs Versus 0.05% Cyclosporine A Monotherapy in Sjögren's Syndrome-Associated Dry Eye: A Paired-Eye Study
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy and safety of topical therapies for ocular involvement in Sjögren's syndrome: a systematic review and network meta-analysis.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To compare the efficacy of combination therapy using 0.05% cyclosporine A (CsA) and absorbable punctal plugs with that of CsA monotherapy in patients with Sjögren's syndrome-associated dry eye (SS-DE) using a paired-eye randomized controlled design. Methods: This prospective, randomized, observer-masked, paired-eye clinical trial included 21 patients (42 eyes) with SS-DE. One eye of each patient received 0.05% CsA plus an absorbable lower punctal plug, whereas the contralateral eye received CsA monotherapy. Clinical assessments, including the Ocular Surface Disease Index (OSDI), visual analog scale (VAS), noninvasive tear breakup time (NIBUT), tear meniscus height (TMH), and corneal dendritic cell (DC) density (measured via Results: After 3 months, both groups showed significant improvements across all parameters ( Conclusion: Combination therapy with 0.05% CsA and absorbable punctal plugs yields superior improvements in both objective clinical signs and subjective symptoms compared to CsA monotherapy in SS-DE. This approach may enhance drug efficacy and patient comfort, offering an optimal therapeutic strategy for autoimmune-related dry eye. Clinical trial registration: [ClinicalTrials.gov] Identifier: NCT07171710.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.